
Mar 3, 2025, 10:24
ASCO’s new living guideline update for Stage IV NSCLC with Driver Alterations
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“The American Society of Clinical Oncology’s (ASCO) new living guideline update, Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, is now available.
Updated recommendations include that clinicians can now consider osimertinib combined with platinum-based chemotherapy or the combination of amivantamab and lazertinib as potential treatment options.
Read more.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22